Finance

Lists
Q2 2026 earnings • released • EPS beat +5.34%
See results
NMRA:NASDAQ
Neumora Therapeutics Inc
$1.50
-6.25%
(-0.10) 1D
Aug 17, 11:23:56 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NMRA...
Open
$1.55
High
$1.58
Low
$1.48
Mkt. cap
277.93M
Avg. vol.
761.42K
Volume
225.22K
52-wk high
$3.65
52-wk low
$0.83
EPS
-$1.33
Shares outstanding
185.28M
No. of employees
63
Open
$1.55
High
$1.58
Low
$1.48
Mkt. cap
277.93M
Avg. vol.
761.42K
Volume
225.22K
52-wk high
$3.65
52-wk low
$0.83
EPS
-$1.33
Shares outstanding
185.28M
No. of employees
63
News stories
From web sources and news partners
About Neumora Therapeutics Inc
CEO-
Employees63
Founded2019
HeadquartersWatertown, Massachusetts, United States
SectorPharmaceutical industry
Websiteneumoratx.com
Analyst ratings
Based on 6 analysts giving stock ratings to NMRA in the past 3 months
Buy
Buy
5
Hold
0
Sell
1
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for NMRA in the last 3 months.
Highest
Current $1.50
$7.00 (+366.67%)
Average
$5.25 (+250.00%)
Lowest
$4.00 (+166.67%)
Analyst
Recommendation
Action
Price target
Projected
Date
Graig Suvannavejh
Mizuho Securities
Buy
Reiterated
$4.00
+166.7%
08/17/2026
Ami Fadia
Needham
Buy
Reiterated
$5.00
+233.3%
08/14/2026
Myles Minter
William Blair
Buy
Reiterated
-
-
08/14/2026
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
$7.00
+366.7%
07/28/2026
Brian Abrahams
RBC Capital
Buy
Maintained
$5.00
+233.3%
07/13/2026
Tessa Romero
J.P. Morgan
Sell
Maintained
-
-
05/26/2026
Paul Matteis
Stifel Nicolaus
Hold
Maintained
$3.00
+100%
05/12/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$14.00
+833.3%
05/07/2026
Last report
Aug 14, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.23 / -$0.24
+5.34%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
40.52M
44.67M
38.60M
29.28M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
12.18M
13.81M
14.27M
12.91M
Operating expense
52.70M
58.48M
52.86M
42.19M
Total operating expenses
52.70M
58.48M
52.86M
42.19M
Operating income
-52.70M
-58.48M
-52.86M
-42.19M
Other non operating income
7.00K
-269.00K
59.00K
-7.00K
EBT including unusual items
-56.76M
-59.45M
-53.43M
-43.08M
EBT excluding unusual items
-51.76M
-59.45M
-53.43M
-43.08M
Income tax expense
-
-
30.00K
-
Effective tax rate
-
-
-0.06%
-
Other operating expenses
-
-
-
-
Net income
-56.76M
-59.45M
-53.46M
-43.08M
Net profit margin
-
-
-
-
Earnings per share
-0.35
-0.35
-0.30
-0.23
Interest and investment income
1.68M
1.34M
1.23M
935.00K
Interest expense
-747.00K
-2.04M
-1.85M
-1.82M
Net interest expenses
938.00K
-701.00K
-623.00K
-885.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-52.68M
-58.47M
-52.86M
-42.18M
Gain or loss from assets sale
-62.00K
264.00K
-71.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps